Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
BMC Cancer|December 22, 2010
The colorectal cancer disease-specific transcriptome may facilitate the discovery of more biologically and clinically relevant informationWendy L Allen, Puthen V Jithesh, Gavin R Oliver, et al.
Molecular Cancer Therapeutics|January 24, 2007
The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cellsWendy L Allen, Estelle G McLean, John Boyer, et al.
Cancer Research|May 1, 2002
The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolatesDaniel B Longley, John Boyer, Wendy L Allen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2012
Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancerLeanne Stevenson, Wendy L Allen, Richard Turkington, et al.
Molecular Cancer Therapeutics|June 6, 2012
Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cellsWendy L Allen, Richard C Turkington, Leanne Stevenson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Clinical determinants of response to irinotecan-based therapy derived from cell line modelsWendy L Allen, Vicky M Coyle, Puthen V Jithesh, et al.
Molecular Cancer Therapeutics|October 27, 2011
A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancerWendy L Allen, Leanne Stevenson, Vicky M Coyle, et al.
Cancer Immunology Research|May 20, 2016
Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant ChemotherapyPhilip D Dunne, Darragh G McArt, Paul G O'Reilly, et al.
Molecular Cancer Therapeutics|February 28, 2018
The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal CancerNicholas Forsythe, Alaa Refaat, Arman Javadi, et al.
Cell Death & Disease|October 30, 2020
RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancerHajrah Khawaja, Andrew Campbell, Jamie Z Roberts, et al.
Pageof 3